DaVita/$DVA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About DaVita
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
- Ticker
- $DVA
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 78,000
- Headquarters
- Denver, United States
- Website
- www.davita.com
DaVita Metrics
BasicAdvanced
$12B
15.97
$12.11
0.83
-
Price and volume
Market cap
$12B
Beta
0.83
52-week high
$247.49
52-week low
$101.00
Average daily volume
718K
Financial strength
Current ratio
1.467
Quick ratio
1.333
Long term debt to equity
11.904
Total debt to equity
12.42
Interest coverage (TTM)
3.67%
Profitability
EBITDA (TTM)
2,826.192
Gross margin (TTM)
32.36%
Net profit margin (TTM)
6.05%
Operating margin (TTM)
15.11%
Effective tax rate (TTM)
20.66%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
7.52%
Return on equity (TTM)
88.48%
Valuation
Price to earnings (TTM)
15.967
Price to revenue (TTM)
0.944
Price to book
-16.16
Price to tangible book (TTM)
-1.44
Price to free cash flow (TTM)
8.219
Free cash flow yield (TTM)
12.17%
Free cash flow per share (TTM)
23.52
Growth
Revenue change (TTM)
6.45%
Earnings per share change (TTM)
18.73%
3-year revenue growth (CAGR)
6.07%
10-year revenue growth (CAGR)
-0.24%
3-year earnings per share growth (CAGR)
33.80%
10-year earnings per share growth (CAGR)
21.55%
What the Analysts think about DaVita
Analyst ratings (Buy, Hold, Sell) for DaVita stock.
Analyst projections of the future price of DaVita stock.
Bulls say / Bears say
U.S. treatment volumes rose 0.6% year on year in Q2, helped by lower mortality, and management expects 2026 growth near the top of its 0.25–0.50% range. Better volumes can lift revenue across DaVita’s large clinic network. (DaVita)
A broad rollout of expanded haemodialysis could give patients another treatment option and support DaVita’s longer-term growth. The approach was found non-inferior to haemodiafiltration in a clinical trial, and DaVita says it has secured compatible dialysers that can be used on existing machines. (The Motley Fool)
DaVita generated $256 million of free cash flow in Q2 and bought back 2.2 million shares. Sustained cash generation could support further share repurchases and earnings growth per share. (DaVita)
The loss of Affordable Care Act subsidies is pushing some patients away from higher-paying commercial cover, weakening DaVita’s payor mix. Management expects this mix shift to cost about $40 million in 2026 and $70 million in 2027. (Reuters)
Management said the proposed 2027 Medicare rate update trails industry cost trends, while the final payment and phosphate-binder rules remain unsettled. Since government programmes account for much of the business, a reimbursement shortfall could squeeze margins. (The Motley Fool)
Patient-care costs per treatment rose more than 3% year on year in the first half, above management’s full-year cost-growth range. If costs remain elevated, they could absorb the benefit of higher treatment volumes. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
DaVita Financial Performance
Revenues and expenses
DaVita Earnings Performance
Company profitability
Upcoming events
No upcoming events
DaVita News
AllArticlesVideos
Funds containing DaVita
AllUSDEURGBP
Fund name | Fund size | $DVA weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.45% |
iShares Ageing Population£AGES | $953M | 0.45% |
iShares Ageing Population€AGED | $903M | 0.45% |
iShares S&P 500 Equal Weight€O4J0 | $5.1B | 0.20% |
iShares S&P 500 Equal Weight£EWSP | $5.1B | 0.20% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.